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Objectives: Ischemia-reperfusion injury after cardiopulmonary bypass is known to
provoke an inflammatory response, which can be attenuated with steroid pretreat-
ment. Cardiopulmonary bypass is also known to stimulate apoptosis. Induction of the
cellular apoptotic cascade occurs via interaction between two membrane receptors:
Fas and Fas ligand. Both molecules also exist in soluble forms, whose significance
remains undetermined; however, both may have a proinflammatory role. We aimed to
document the temporal profile of soluble Fas and soluble Fas ligand after cardiopul-
monary bypass and to investigate whether steroid pretreatment alters this response.
Methods: The study was of a nonrandomized, nonblinded, prospective nature.
Twenty-seven infants were monitored prospectively, of whom 13 received dexa-
methasone at induction of anesthesia. Soluble Fas, soluble Fas ligand, and inter-
leukin 6 were measured from induction of anesthesia until 24 hours after admission
to the intensive care unit. Data on clinical and laboratory variables were also col-
lected at the same time intervals.
Results: As expected, dexamethasone pretreatment attenuated interleukin 6 release
and the clinical systemic inflammatory response after bypass. Soluble Fas showed
a remarkably similar profile to interleukin 6, in terms of temporal release and atten-
uation with steroids. There was also a correlation between maximum soluble Fas
and markers of capillary leak (colloid requirement and drain loss). Conversely, sol-
uble Fas ligand release was unchanged by cardiopulmonary bypass and steroid
administration. However, patients with higher soluble Fas ligand levels exhibited a
more dramatic drop and delayed recovery in monocyte count, consistent with the
role of this molecule in apoptosis.
Conclusions: Release of soluble Fas and soluble Fas ligand follows a markedly dif-
ferent temporal profile after cardiopulmonary bypass. The similarity between solu-
ble Fas and interleukin 6, together with the attenuation of both with steroids, may
suggest a role for soluble Fas as a proinflammatory marker. 
The systemic inflammatory response accompanying ischemia-reper-fusion injury after cardiopulmonary bypass (CPB) is well docu-mented.1 The mechanisms of this response include activation ofinflammatory cytokine cascades,2 oxidative stress,3 and generationof reactive oxygen species.4
Another important consequence of ischemia-reperfusion injury is the triggering
of apoptotic cell death5 through the Fas/Fas ligand system.6 Fas (also known as
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CD95) is a 45-kd type I membrane-associated glycoprotein
of the tumor necrosis factor receptor family.7 Fas is
expressed in a variety of cells, including cardiomyocytes,
vascular endothelium, and cells of the immune system. Fas
ligand (FasL) is a 40-kd type II membrane protein, akin to
tumor necrosis factor-α, found predominantly on activated
T cells and natural killer cells.7 Apoptosis occurs when
FasL binds to Fas, resulting in trimerization of Fas, caspase
activation, and cell death.8
Both Fas and FasL also exist in soluble forms (sFas,
sFasL), which can be produced de novo or from conversion
of the membrane-bound form by a metalloproteinase.9,10
The importance of the membrane-bound form of these mol-
ecules in a variety of disease states is increasingly recog-
nized, although the significance of the soluble form of Fas
and FasL has yet to be fully elucidated.11-20 Ischemia-reper-
fusion injury akin to CPB produces myocardial sFasL
release and apoptosis in animals6; whether this also happens
in humans is unknown. Interestingly, membrane-bound FasL
on vascular endothelium may be involved in maintenance of
vascular integrity, with loss of FasL leading to capillary
leak,21 a common phenomenon after CPB. If so, loss of
expression of membrane-bound FasL by conversion to
sFasL should result in higher sFasL levels and greater capil-
lary leak after CPB. Soluble Fas is also found in conditions
of acute and chronic inflammation.11-13,17-20,22-26 These data
suggest that both sFasL and sFas may also possess proin-
flammatory properties, in addition to their apoptotic roles.
Proinflammatory cytokine release is attenuated by pre-
treatment with steroids, which has potentially beneficial
clinical implications.27,28 However, what effect, if any,
steroid administration may have on sFas/sFasL release in
the clinical setting is unknown.
We have conducted an observational study examining 3
issues: (1) documentation of the time course of release of
sFas/sFasL after CPB, (2) whether pretreatment with dex-
amethasone alters this response in terms of (a) sFas/sFasL
release and (b) the clinical inflammatory response with cap-
illary leak after CPB, and (3) whether levels of either mol-
ecule relate to an indirect indicator of apoptosis as
measured by the absolute monocyte count.
Patients and Methods
The study was of a prospective, observational nature. Institutional
ethical approval was given, and informed consent for blood sam-
pling was obtained from patients’ parents or legal guardians before
enrolment. Twenty-seven patients undergoing surgical repair of
congenital heart defects were studied. Patients either were given
dexamethasone (DEX; 0.25 mg/kg) at induction of anesthesia (n =
14) or were not given DEX (n = 13) according to anesthetic pref-
erence. The surgical, anesthetic, and pediatric intensive care unit
(PICU) staff were unaware of the study objectives. Sample size
was not calculated because the temporal profiles of sFas and sFasL
were unknown.
Potential confounding variables were recorded and included
the following: age, weight, sex, and duration of CPB, aortic cross-
clamping, and circulatory arrest. Arterial blood samples were
taken and clinical variables recorded at the following time points:
induction of anesthesia, immediately after cessation of CPB before
protamine administration, and 1, 6, 12, and 24 hours after admis-
sion to the PICU. Interleukin 6 (IL-6) was measured in addition to
sFas and sFasL. IL-6 was chosen as a typical marker of cytokine
response, because the time course of release of this cytokine and
its attenuation with steroid is well documented.27-29 Clinical and
laboratory variables reflecting systemic inflammatory response
and capillary leak in the first 24 hours are detailed below.
Anesthesia
Anesthetic induction consisted of intravenous fentanyl (5 µg/kg)
or ketamine (1 mg/kg). Inhaled isoflurane (0.5%) and intermittent
bolus intravenous fentanyl (10 µg/kg) were used for maintenance.
Neuromuscular blockade was achieved with bolus intravenous
pancuronium (100 µg/kg).
CPB
Heparin (3 mg/kg) was administered before commencement of
CPB to maintain activated clotting times greater than 480 seconds
during bypass, and anticoagulation was reversed with protamine
sulphate after discontinuation of CPB. 
The extracorporeal system was non–heparin bonded and con-
sisted of the following: roller pump (Sarns 9000; Terumo
Cardiovascular Systems, Ann Arbor, Mich), oxygenator (Polystan
A/S, Copenhagen, Denmark), Polystan Safe Micro (patients <10
kg), Polystan Safe Mini (patients 10-15 kg), and Terumo Capoix
SX10 (patients >15 kg). All patients received slow continuous
utrafiltration while on bypass (Gambro FH 22 and 66 filters
[Gambro BCT, Stockholm, Sweden] for patients < 5 kg and
Minntech HPH 400 [Minntech Corporation, Minneapolis, Minn] for
those > 5 kg). Priming solution comprised packed red cells (to main-
tain hematocrit value > 24% on bypass), sodium bicarbonate (8.4%)
20 mL/L for clear primes and 1 mL/bag of packed red cells, manni-
tol (20%) 2 mL/kg body weight, heparin 250 IU/kg body weight,
Hartmann’s solution in equal volumes with Haes-Steril (only with
clear primes), or Haes-Steril (10%) as the remainder of the priming
volume. Patients weighing less than 7 kg received 50 mL of fresh
frozen plasma in the prime, replacing the equivalent volume of clear
fluid. CPB was initiated at a cardiac index of 2.6 L · min-1 · m-2 and
maintained at this flow rate regardless of the degree of induced
hypothermia. Flow was nonpulsatile, and an alpha-stat blood gas
strategy was used. Warm blood cardioplegia was used in all patients.
Blood Sampling
All blood samples were taken from indwelling arterial catheters
from the radial, brachial, or femoral artery. Two milliliters of
blood was placed in a tube containing ethylenediaminetetraacetic
acid and immediately centrifuged at 4°C for 10 minutes at 10,000
rpm. Plasma was aspirated, transferred to cryovials, and stored at
–80°C before biochemical analysis. IL-6, sFas, and sFasL levels
were measured by double sandwich enzyme-linked immunosor-
bent assay using a commercial kit (Bendermed Systems;
Medsystems Diagnostics, Vienna, Austria). 
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Clinical and Other Laboratory Variables
Perioperative clinical data were collected from the patient obser-
vation charts at the time points defined above and included heart
rate, arterial and central venous pressures, rectal (core) tempera-
ture, urine output, cumulative surgical drain losses, and colloid
transfusion requirement. Colloid replacement was not protocol
driven, but rather tailored to individual patients’ metabolic and
hemodynamic profiles, guided by the senior PICU clinician and
surgeon.
Whole blood lactate, arterial blood gas parameters, hemoglo-
bin concentration, platelets, total leukocyte, neutrophil, monocyte,
and lymphocyte counts, blood urea nitrogen, creatinine, and coag-
ulation parameters (international normalized ratio and activated
partial thromboplastin ratio) were also measured postoperatively
at the same time points.
Leukocyte Subsets
Leukocyte subsets were measured in an automated fashion by a
Beckman Coulter counter (Beckman Coulter, Inc, Fullerton,
Calif). We chose to use monocyte counts as an indirect marker of
apoptosis for 2 reasons: (1) monocytes are known to express sig-
nificant levels of Fas30 and are susceptible to FasL-induced apop-
tosis in vitro31 and (2) monocytes are prone to steroid-induced
apoptosis via the Fas/FasL pathway in vitro.32,33 Lymphocytes do
not express Fas as uniformly as monocytes (only memory
CD45RO+ lymphocytes express Fas),34 and the steroid effect is
dependent on the stage of the lymphocyte subtype and cell cycle.35
Neutrophils express high levels of sFas,30 but the effect of sFasL
is chemotactic as well as apoptotic.36 In addition, many cytokines,
including IL-6, exhibit anti-apoptotic properties toward neu-
trophils,37 and steroids inhibit apoptosis.38 Thus, interpretation of
changes in lymphocyte and neutrophil numbers is problematic.
Statistical Analysis
Demographic data were assumed non-normal and compared by
use of the nonparametric Mann-Whitney test. Sequential variables
followed over time were compared by use of 2-way repeated-
measures analysis of variance (SPSS 10.5; SPSS, Inc, Chicago,
Ill). The analysis of variance model was of the general linear mea-
sures type and used marginal (type III) sums of squares because of
nonorthogonality between the treatment and placebo groups. In
addition, non-normal data (IL-6 and sFas only) were log trans-
formed before analysis. Analysis of variance results are reported
as group (treatment) effect, time effect, and interaction
(group/time) effect.39
A multiple regression model was used to explore whether max-
imum sFas, sFasL, or IL-6 levels were independently associated
with duration of CPB, aortic crossclamping, circulatory arrest, or
DEX administration.
TABLE 1. Demographic and CPB data
Variable Placebo (n = 14) DEX (n = 13) P value
Age (mo) 7.5 (2.5-9.8) 2.0 (0.1-10.0) .38
Weight (kg) 6.5 (4.3-9.4) 4.0 (3.3-7.0) .22
Sex (M:F) 11:3 7:6 .24
CPB (min) 99 (82-124) 74 (70-110) .15
Aortic crossclamp (min) 65 (42-74) 48 (45-74) .58
Circulatory arrest (n) 4 6 .69
Data are median (interquartile range).
Figure 1. Change in concentration of IL-6 (A), sFas (B), and sFasL
(C) after CPB. Time points include induction of anesthesia, imme-
diately after cessation of CPB before protamine administration,
and 1, 6, 12, and 24 hours after PICU admission, as defined in the
“Methods” section. Data for IL-6 and sFas are log transformed;
points represent mean and error bars, SEM.
A
B
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Operation Type and Patient Demographics 
Operations were as follows: arterial switch procedure (n = 4),
tetralogy of Fallot correction (n = 4), hypoplastic aortic arch repair
(n = 4, 3 included a ventricular septal defect), aortic valve aug-
mentation/replacement after prior truncus arteriosus repair (n = 3),
Norwood stage 1 (n = 2), complete atrioventricular septal defect
repair (n = 2), complete correction of pulmonary atresia with ven-
tricular septal defect (n = 2, 1 included unifocalization of major
aortopulmonary collaterals), and Fontan, hemi-Fontan, atrial sep-
tal defect closure, repair of left atrioventricular valve, ventricular
septal defect closure, and resection of subaortic stenosis (n = 1
each). Groups were well matched in terms of age, weight, sex, and
duration of CPB, aortic crossclamping, and circulatory arrest
(Table 1).
Results
IL-6, sFas, and sFasL Levels
IL-6 was undetectable in all but 4 patients (2 DEX, 2
placebo) preoperatively. All 4 were receiving infusions of
alprostadil (prostaglandin E1) to maintain ductal patency.
After CPB, IL-6 rose rapidly until 1 hour after admission to
the PICU. After this time the rate of rise slowed consider-
ably, peaking in placebo patients at 12 hours, giving median
(interquartile range) levels of 424 pg/mL (188-584 pg/mL).
In contrast, peak levels in DEX patients (also at 12 hours)
were considerably lower, at 65 pg/mL (22-77 pg/mL).
Although both groups showed a rise in IL-6 over time (time
effect P < .001), the rise was considerably blunted in the
DEX group (interaction effect P < .01). Log transformed
data are shown in Figure 1, A.
Soluble Fas was detectable preoperatively in 9 patients
(4 DEX, 5 placebo). Interestingly, only 1 of these also had
detectable levels of IL-6. Overall, the pattern of change in
sFas showed a similarity to IL-6 in terms of correlation (r =
0.43, P < .0001 for log-transformed values) and the attenu-
ation with DEX (Figure 1, B). However, the rate of rise in
sFas was less dramatic than that of IL-6, with peak levels
also occurring at 12 hours in placebo patients, 0.42 ng/mL
(0.13-0.65 ng/mL). The peak occurred later, at 24 hours,
0.21 ng/mL (0-0.33 ng/mL), in DEX-treated patients. Like
IL-6, sFas levels were elevated over time in both groups
(time effect P < .001), and the response was attenuated in
the DEX group (interaction effect P < .03). 
Soluble FasL levels did not, however, differ between
groups (group effect P = .29), nor did they change consis-
tently over time (time P = .25, interaction P = .57) (Figure
1, C). Levels were detectable in all patients preoperatively.
For placebo patients, the median preoperative and 24-hour
levels were 0.844 ng/mL (0.703-0.984 ng/mL) and 0.844
ng/mL (0.750-0.922 ng/mL), respectively. Corresponding
levels for DEX patients were 0.875 ng/mL (0.813-1.188
ng/mL) and 0.875 ng/mL (0.688-1.000 ng/mL), respec-
tively. Soluble FasL showed no relationship with log sFas (r
= 0.004, P = .97). It is notable that levels of both sFas and
sFasL dropped immediately after CPB. This is likely to be
due to ultrafiltration while on CPB; certainly both mole-
cules are small enough to be effectively filtered; however,
we did not specifically measure their relative concentrations
in the ultrafiltrate.
TABLE 2. Selected clinical and laboratory variables over time 
Time ANOVA P value
Group Before CPB After CPB 1 h 6 h 12 h 24 h Group Time Inter.
Heart rate (beats/min) D 124 (24) 147 (24) 148 (26) 139 (18) 137 (19) 140 (17) .25 <.001 .06
P 118 (30) 158 (26) 158 (23) 159 (17) 159 (13) 138 (20)
Temp (°C) D 36.7 (0.4) 35.9 (1.0) 36.8 (1.1) 36.7 (1.0) 36.9 (1.0) .04 <.001 .56
P 36.8 (0.3) 36.4 (1.4) 37.5 (1.1) 37.4 (1.0) 37.3 (0.5)
pH D 7.41 (0.06) 7.43 (0.10) 7.41 (0.09) 7.41 (0.12) 7.40 (0.06) 7.41 (0.06) .02 .19 .62
P 7.40 (0.07) 7.39 (0.12) 7.32 (0.15) 7.40 (0.07) 7.35 (0.06) 7.36 (0.05)
PCO2 (kPa) D 4.3 (1.5) 4.8 (2.1) 4.9 (1.5) 4.6 (1.6) 4.8 (1.5) 4.4 (0.8) .34 .76 .70
P 5.1 (1.0) 4.5 (0.8) 5.2 (1.2) 4.6 (0.9) 4.9 (1.1) 4.9 (0.7)
Base excess D –0.3 (3.7) –1.3 (3.2) –1.0 (2.4) –1.6 (2.6) –1.2 (3.6) –1.8 (2.6) .14 .11 .26
P –0.4 (3.2) –2.7 (4.9) –4.6 (5.7) –1.6 (3.4) –3.3 (2.8) –2.2 (3.6)
Lactate (mmol/L) D 3.3 (2.7) 3.1 (2.5) 2.1 (1.4) 1.6 (1.0) 1.0 (0.6) .09 <.001 .76
P 4.0 (2.4) 3.7 (2.1) 3.2 (1.7) 2.4 (1.8) 2.3 (2.4)
INR D 1.3 (0.4) 1.8 (0.4) 1.5 (0.4) 1.5 (0.4) 1.4 (0.3) .09 <.001 .29
P 1.3 (0.4) 2.1 (0.5) 1.8 (0.6) 1.7 (0.5) 1.8 (0.6)
APTT D 1.3 (0.3) 2.1 (1.0) 1.6 (0.6) 1.6 (1.0) 1.3 (0.3) .53 <.001 .90
P 1.2 (0.3) 2.1 (1.0) 1.7 (0.7) 1.6 (0.6) 1.5 (0.3)
Data are mean (SD). ANOVA, Analysis of variance; inter., interaction; D, dexamethasone group; P, placebo group; INR, international normalized ratio; APTT,
activated partial thromboplastin time.
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Multiple regression analysis was performed with the use
of the following independent variables: age, use of DEX,
duration of CPB, duration of aortic crossclamping, and
occurrence of circulatory arrest. Use of DEX was the only
independent predictor for both maximum IL-6 (P < .001)
and sFas (P = .04) levels. There was a little evidence of an
independent association between duration of CPB and max-
imum sFas (P = .08). No variable independently predicted
maximum sFasL level.
Markers of Systemic Inflammation
Selected results are shown in Table 2. The change in heart
rate over time (time effect P < .001) was more pronounced
in placebo patients (interaction effect P = .06). This group
demonstrated maximal tachycardia at 6 and 12 hours after
PICU admission, coinciding with the maximum tempera-
ture difference between groups. Temperature varied over
time (P < .001) and was higher in the placebo group (group
effect P = .04). Placebo patients had a slightly lower pH
(group effect P = .02); this tended to be mixed in origin, as
no differences were seen in PCO2 or base deficit when ana-
lyzed individually. Lactate levels fell over time in both
groups. Levels were generally lower in DEX patients
(group effect P = .09). 
Over the first 24 hours, placebo patients had higher median
(interquartile) cumulative drain losses: 25 mL/kg (18-35
mL/kg) versus 17 mL/kg (11-22 mL/kg) (P = .06). This was
reflected by a greater colloid requirement to maintain hemo-
dynamic parameters: 63 mL/kg (41-131 mL/kg) versus 11
mL/kg (10-64 mL/kg) (P = .02). This was not due to a differ-
ence in coagulation parameters between groups (Table 2),
suggesting a higher capillary leak in placebo patients. 
For all patients, the maximal logarithmic sFas value cor-
related both with cumulative drain loss (r = 0.37, P = .06)
and 24-hour colloid requirement (r = 0.55, P < .01). There
were no correlations between maximum sFasL levels and
either drain loss (r = –0.007, P = .97) or colloid requirement
(r = 0.10, P = .62).
Figure 2. Change in total leukocyte, lymphocyte, monocyte, and neutrophil counts after CPB. Time points include induction
of anesthesia, immediately after cessation of CPB before protamine administration, and 1, 6, 12, and 24 hours after PICU
admission. Data points represent mean and error bars, SEM.
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There were no overall differences for mean arterial and
central venous pressures, urine output, serum creatinine, or
blood urea nitrogen values between groups, although creat-
inine and blood urea nitrogen rose in both groups over 24
hours (data not shown).
Leukocyte Subsets
Both groups demonstrated a marked fall in total white blood
cell count immediately after CPB, which was primarily due
to an acquired lymphopenia and monopenia (time effects for
all groups P < .001) (Figure 2). The fall in both the lympho-
cytes and monocytes tended to be more pronounced among
DEX patients (interaction effects P = .09 and P = .08). 
As an indirect marker for apoptosis, the absolute mono-
cyte count correlated negatively with absolute sFasL (r =
–0.29, P = .002) and positively with log sFas (r = 0.37, P <
.0001) (Figure 3). However, the correlation with log sFas was
spurious, because the only independent predictor of mono-
cyte count from a multiple regression model incorporating
the 2 parameters was sFasL (standardized β –.59, P = .04).
Lymphocyte counts correlated independently with nei-
ther sFasL (standardized β –.09, P = .33) nor log sFas (stan-
dardized β .02, P = .84). Absolute neutrophil counts rose
comparably in both groups over the study period and corre-
lated independently with log Fas (standardized β = .29, P =
.003) but not sFasL (standardized β = –.09, P = .35).
There were no differences in hemoglobin and platelets
between groups (all P > .58); both fell after CPB and nei-
ther recovered completely by 24 hours (data not shown).
Discussion
We sought to examine 3 issues in this study: (1) to docu-
ment the temporal profile of the release of sFas and sFasL
after CPB in children; (2) to see whether steroid pretreat-
ment altered these profiles; and (3) to see whether either of
these molecules related to an indirect marker of apoptosis,
namely the change in monocyte count. Results are dis-
cussed in terms of sFas, then sFasL.
Soluble Fas
Release of sFas release after CPB showed a remarkable
similarity to release of IL-6, both in the pattern of rise (r =
0.43, P < .0001) and in the attenuation with steroid pre-
treatment (Figure 1). In addition, there was a trend for
higher peak sFas levels with longer CPB times (P = .08).
Steroid pretreatment translated clinically into reduced sys-
temic inflammatory response (heart rate, temperature, aci-
dosis, and lactate) and capillary leak (drain losses and
colloid requirement). In addition, the parameters of capil-
lary leak correlated with maximum sFas levels. The attenu-
ation of cytokine release and clinical inflammation after
CPB with steroid pretreatment has been documented by
others,27,28 but the role of sFas in this setting has not.
Membrane-bound Fas is known to be a death receptor,
whose role is primarily one of initiating the apoptotic cas-
cade after ligation by membrane-bound FasL from activated
T cells, natural killer cells, and macrophages.7 Membrane-
bound Fas may also be converted to its soluble form after
cleavage by specific metalloproteinases. The role of sFas
has yet to be fully elucidated. Certainly the inference from
this study is that sFas may be a marker of inflammation.
This is consistent with other reports, in which sFas has been
shown to be elevated in conditions involving an active
inflammatory process.11-13,17-20
Soluble Fas Ligand
The release of sFasL after CPB was quite different from that
of sFas. Soluble FasL was detectable in all patients preop-
eratively, compared with one third of patients (9/27) for
sFas. Neither CPB nor DEX pretreatment influenced sFasL
release. It is unknown whether sFasL levels equate with
leukocyte membrane-bound FasL expression. If so, then
high levels of sFasL should be associated with increased
apoptosis. A limitation of this study is that we had no means
of measuring apoptosis directly; however, we used the
absolute monocyte count as an indirect marker of apoptosis.
Monocytes are known to be susceptible to glucocorticoid-
induced apoptosis,32 mediated via the Fas/FasL pathway.33
In our study, monocyte counts were lowest when sFasL
were highest (r = –0.29, P = .002). However, sFasL levels
were not obviously different between steroid-treated and
nontreated groups, suggesting factors other than steroids
may have influenced sFasL levels. For example, the pro-
Figure 3. Scattergram showing the negative correlation between
absolute monocyte count and sFasL.
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nounced monocyte drop and slower recovery among DEX-
treated patients (Figure 2) may have been exacerbated by
the lower levels of sFas. It has been postulated that sFas
may serve to block apoptosis by binding to membrane-
bound FasL.40 Thus, the delayed monocyte recovery in the
DEX group may be due to the reduction in sFas release
rather than to increasing membrane-bound FasL expression
and lymphocyte activation. However, it must be stressed
that this remains purely speculative without an objective in
vivo measure of apoptosis. Nonetheless, it is reasonable to
assume that the drop in monocytes was due to apoptosis
rather than extravasation, margination, or purely a CPB
hemodilution or filtration effect, because neutrophil num-
bers did not decrease.
Regarding the potential proinflammatory role of FasL, it
has been shown that membrane-bound FasL is also
expressed on vascular endothelium and is shed before
leukocyte extravasation.21 Shedding of membrane-bound
FasL results in increased sFasL; thus, one would expect
higher levels of sFasL to be seen in patients with greatest
capillary leak and leukopenia. This was not the case, as
sFasL correlated with neither drain loss nor colloid require-
ment nor did it correlate negatively with neutrophil or lym-
phocyte counts. In addition, sFasL did not correlate with
sFas; thus, we conclude that sFasL cannot be used as an
inflammatory marker in these circumstances. The reason
may be that sFasL does not accurately reflect endothelial
membrane–bound FasL expression.
Limitations of the Study
The study was nonrandomized and nonblinded. The deci-
sion to use steroids was governed by anesthetic preference
and was thus governed by the day of the week the child was
allocated for the operation. However, allocation was per-
formed by a team who were unaware of the study objec-
tives, and that is borne out by the adequate matching of
variables shown in Table 1. Also, the clinicians involved in
the PICU care were unaware that a link between steroid
administration and clinical variables was being examined.
We were unable to perform an objective measure of
apoptosis, and we did not measure the membrane-bound
forms of Fas or FasL, which are known to be of far greater
importance in the apoptotic cascade. Thus, any conclusions
we may draw regarding apoptosis remain speculative and
are limited to associations with the soluble forms of these
molecules only.
It would be of interest to examine whether the change in
clinical markers of inflammation translated into outcome data
(eg, mortality, duration of ventilation); however, we did not
attempt this analysis because the small sample size lacked sta-
tistical power. For the same reason, we cannot exclude a type
2 error in the multiple regression model examining CPB-
related factors and maximum sFas, sFasL, and IL-6 levels. 
In summary, our findings suggest a possible proinflam-
matory role for sFas after CPB. Indeed the release of this
molecule is attenuated by steroid pretreatment in a manner
similar to the cytokine IL-6. This finding needs clarification
in future studies. Expression of sFasL, on the other hand,
showed no alteration with CPB or steroids, nor did it corre-
late with markers of vascular leak. However, the negative
correlation with monocyte count is consistent with its role
in apoptosis.
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